Graus Y F, de Baets M H, Parren P W, Berrih-Aknin S, Wokke J, van Breda Vriesman P J, Burton D R
The Scripps Research Institute, Department of Immunology, La Jolla, CA 92037, USA.
J Immunol. 1997 Feb 15;158(4):1919-29.
Myasthenia gravis (MG) is a prototype Ab-mediated autoimmune disease in which Abs against nicotinic acetylcholine receptors (AChR) induce loss of functional receptors at the neuromuscular junction. Germinal centers present in MG hyperplastic thymus contain activated B cells spontaneously producing anti-human AChR (anti-huAChR) Ab in vitro. To access the anti-huAChR repertoire, phage display Fab libraries of thymic lymphocytes were constructed from two MG patients. Four Fabs highly specific for huAChR were isolated that bind to determinants in or near the main immunogenic region. These anti-huAChR Fabs showed evidence of significant somatic mutations, supporting the idea that the anti-huAChR Ab response in MG patients is driven by Ag. Two Fabs were able to inhibit up to 90% of donor serum anti-huAChR Abs. Competition with serum anti-huAChR Ab was also observed in unrelated MG patients and indicate that anti-huAChR Fabs bind to epitopes on huAChR recognized by the majority of MG patients. In vitro antigenic modulation studies demonstrated that anti-huAChR Fabs were able to induce AChR loss when cross-linked by an anti-Fab Ab but not as monovalent Fab. Moreover, anti-huAChR Fabs were able to protect against AChR loss by antigenic modulation induced by MG serum Abs, suggesting a potential therapeutic role for these recombinant Fabs in patients with a myasthenic crisis.
重症肌无力(MG)是一种典型的由抗体介导的自身免疫性疾病,其中针对烟碱型乙酰胆碱受体(AChR)的抗体导致神经肌肉接头处功能性受体丧失。MG增生性胸腺中的生发中心含有在体外能自发产生抗人AChR(抗huAChR)抗体的活化B细胞。为了获取抗huAChR抗体库,从两名MG患者构建了胸腺淋巴细胞的噬菌体展示Fab文库。分离出了四种对huAChR具有高度特异性的Fab,它们与主要免疫原性区域内或附近的决定簇结合。这些抗huAChR Fab显示出明显的体细胞突变证据,支持了MG患者中抗huAChR抗体反应由抗原驱动的观点。两种Fab能够抑制高达90%的供体血清抗huAChR抗体。在无关的MG患者中也观察到与血清抗huAChR抗体的竞争,这表明抗huAChR Fab与大多数MG患者所识别的huAChR表位结合。体外抗原调节研究表明,抗huAChR Fab在被抗Fab抗体交联时能够诱导AChR丧失,但作为单价Fab则不能。此外,抗huAChR Fab能够防止由MG血清抗体诱导的抗原调节导致的AChR丧失,这表明这些重组Fab在重症肌无力危象患者中具有潜在的治疗作用。